Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 23, 2011, Pages 7120-7128

  Mathew, Bini ^a   Srivastava, Shefali ^a   Ross, Larry J ^a   Suling, William J ^a   White, E Lucile ^a   Woolhiser, Lisa K ^b   Lenaerts, Anne J ^b   Reynolds, Robert C ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Antitubercular; FtsZ inhibitor; Pyridopyrazine; Pyrimidothiazine

Indexed keywords

2 ALKOXYCARBONYLAMINOPYRIDINE; ETHYL 6 AMINO 4 [[4 (DIETHYLAMINO)BUTYL]AMINO] 5 NITRO 2 PYRIDINECARBAMATE; ETHYL 6 AMINO 4 [[4 (DIETHYLAMINO)ETHYL]AMINO] 5 NITRO 2 PYRIDINECARBAMATE; ETHYL 6 AMINO 4 [[4 (DIMETHYLAMINO)ETHYL]AMINO] 5 NITRO 2 PYRIDINECARBAMATE; ETHYL [4 CHLORO 6 [[4 (DIETHYLAMINO)BUTYL]AMINO]PYRIMIDIN 2 YL]CARBAMATE; ETHYL [4 CHLORO 6 [[5 (DIETHYLAMINO)PENTAN 2 YL]AMINO]PYRIMIDIN 2 YL]CARBAMATE; ETHYL [8 [[2 (DIETHYLAMINO)ETHYL]AMINO] 2,3 DI(FURAN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[2 (DIETHYLAMINO)ETHYL]AMINO] 2,3 DI(THIOPHEN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[2 (DIETHYLAMINO)ETHYL]AMINO] 2,3 DIPHENYLPYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 2,3 DI(FURAN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 2,3 DI(THIOPHEN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 2,3 DIPHENYLPYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[4 (DIETHYLAMINO)BUTYL]AMINO] 2,3 DI(FURAN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[4 (DIETHYLAMINO)BUTYL]AMINO] 2,3 DI(THIOPHEN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[4 (DIETHYLAMINO)BUTYL]AMINO] 2,3 DIPHENYLPYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[5 (DIETHYLAMINO)PENTAN 2 YL]AMINO] 2,3 DI(FURAN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[5 (DIETHYLAMINO)PENTAN 2 YL]AMINO] 2,3 DI(PYRIDIN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[5 (DIETHYLAMINO)PENTAN 2 YL]AMINO] 2,3 DI(THIOPHEN 2 YL)PYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[5 (DIETHYLAMINO)PENTAN 2 YL]AMINO] 2,3 DIETHYLPYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; ETHYL [8 [[5 (DIETHYLAMINO)PENTAN 2 YL]AMINO] 2,3 DIMETHYLPYRIDO[2,3 B]PYRAZIN 6 YL]CARBAMATE; FTSZ PROTEIN; FTSZ PROTEIN INHIBITOR; N8 [5 (DIETHYLAMINO)PENTAN 2 YL] 2,3 DI(FURAN 2 YL)PYRIDO[2,3 B]PYRAZINE 6,8 DIAMINE; N8 [5 (DIETHYLAMINO)PENTAN 2 YL] 2,3 DI(THIOPHEN 2 YL)PYRIDO[2,3 B]PYRAZINE 6,8 DIAMINE; PYRAZINE DERIVATIVE; PYRIDOPYRAZINE DERIVATIVE; PYRIMIDOTHIAZINE DERIVATIVE; THIAZINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; TUBERCULOSIS; VERO CELL;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PYRAZINES; PYRIDINES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZINES;

MYCOBACTERIUM TUBERCULOSIS;

EID: 80655136978     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.09.062     Document Type: Article

References (21)

1. R.C. Goldman, and B.E. Laughon Tuberculosis (Edinb) 89 2009 331
2. A. Koul, E. Arnoult, N. Lounis, J. Guillemont, and K. Andries Nature 469 2011 483
3. H.P. Erickson Cell 80 1995 367
4. J. Wang, A. Galgoci, S. Kodali, K.B. Hearth, H. Jayasuriya, K. Dorso, F. Vicente, A. Gonzalez, D. Cully, D. Bramhill, and S. Singh J. Biol. Chem. 278 2003 44424
5. D.N. Margailt, L. Romberg, R.B. Mets, A.M. Hebert, T.J. Mitchinson, M.W. Krischner, and D.R. Chaudhuri Proc. Natl. Acad. Sci. U.S.A. 101 2004 11821
6. G. Urgaonkar, S.L.H. Pierre, I. Meir, H. Lund, D.R. Chaudhuri, and J.T. Shaw Org. Lett. 7 2005 5609
7. Q. Huang, F. Kirikae, T. Kirikae, A. Pepe, A. Amin, L. Respicio, R.A. Slaydon, P.J. Tonge, and I. Ojima J. Med. Chem. 49 2006 463
8. D.J. Haydon, N.R. Stokes, R. Ure, G. Galbraith, J.M. Bennett, D.R. Brown, P.J. Baker, V.V. Barynin, D.W. Rice, S.E. Sedelnikova, J.R. Heal, J.M. Sheridan, S.T. Aiwale, P.K. Chauhan, A. Srivastava, A. Taneja, I. Collins, J. Errington, and L.G. Czaplewski Science 321 2008 1673
9. K. Kumar, D. Awasthi, S.-Y. Lee, I. Zanardi, B. Ruzsicska, S. Knudson, P.J. Tonge, R.A. Slayden, and I. Ojima J. Med. Chem. 54 2011 374
10. K. Kumar, D. Awasthi, W.T. Berger, P.J. Tonge, R.A. Slayden, and I. Ojima Future Med. Chem. 2 2010 1305
11. E.L. White, W.J. Suling, L.J. Ross, L.E. Seitz, and R.C.J. Reynolds Antimicrob. Chemother. 50 2002 111
12. R.C. Reynolds, S. Srivastava, L.J. Ross, W.J. Suling, and E.L. White Bioorg. Med. Chem. Lett. 14 2004 3161
13. C. Temple, J.D. Rose, R.D. Elliot, and J.A. Montgomery J. Med. Chem. 11 1968 1216
14. R.D. Elliot, C. Temple, and J.A. Montgomery J. Org. Chem. 31 1966 1890
15. I.V. Boldyrev, I.F. Valdimirtsev, E.A. Romanenko, N.G. Korzhe-Nevskaya, E.V. Titov, and V.M. Cherkasov Chem. Heterocycl. Compd. USSR 1977 1006
16. D.E. O'Brien, C.C. Cheng, and W.J. Pfleiderer J. Med. Chem. 9 1966 573
17. C. Temple, G.P. Wheeler, R.N. Comber, R.D. Elliot, and J.A. Montgomery J. Med. Chem. 26 1983 1614
18. S. Ananthan, E.R. Faaleolea, R.C. Goldman, J.V. Hobrath, C.D. Kwong, B.E. Laughon, J.A. Maddry, A. Mehta, L. Rasmussen, R.C. Reynolds, J.A. Secrist, N. Shindo, D.N. Showe, M.I. Sosa, W.J. Suling, and E.L. White Tuberculosis 89 2009 334
19. C.G. Temple Chemistry & Biology of Pteridines 1990 Walter de Gruyter & Co. New York pp 1009-1014
20. C. Temple, and G.A. Rener J. Med. Chem. 35 1992 4809
21. A.J. Lenaerts, V. Gruppo, J.V. Brooks, and I.M. Orme Antimicrob. Agents Chemother. 47 2003 783